Crinetics Pharmaceuticals reported revenue of $25.12M and net income of -$120.43M for the quarter ended Jun 2026. This income statement covers 37 quarters of results from Jun 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 38.62M | 38.44M | 47.80M | 53.72M | 53.80M | 53.88M | 53.99M | 54.68M | 66.71M | 68.17M | 78.54M | 79.32M | 80.84M | 92.93M | 93.53M | 94.13M | 94.55M | 95.58M | 105.31M | 105.81M | |||||||||||||||||
| Revenue & cost | |||||||||||||||||||||||||||||||||||||
| Revenue | 1.08M | 3.13M | 0.44M | 0.46M | 0.71M | 2.68M | 0.99M | 0.35M | 0.64M | 0.40M | 0.36M | 1.03M | 0.14M | 6.16M | 10.73M | 25.12M | |||||||||||||||||||||
| Gross Profit | 0.36M | 1.03M | 10.53M | 24.96M | |||||||||||||||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 21.58M | 24.60M | 28.25M | 32.99M | 31.99M | 36.99M | 38.47M | 40.64M | 43.84M | 45.58M | 53.34M | 58.34M | 61.91M | 66.57M | 76.24M | 80.30M | 90.46M | 85.05M | 100.08M | 99.85M | |||||||||||||||||
| Selling, General & AdministrativeSG&A | 6.23M | 7.36M | 8.71M | 10.49M | 11.93M | 11.27M | 12.19M | 13.34M | 15.48M | 17.08M | 20.83M | 24.84M | 25.89M | 28.18M | 35.53M | 49.84M | 52.27M | 53.70M | 50.83M | 57.57M | |||||||||||||||||
| Other Operating ExpensesOther Opex | 1.08M | 0.20M | 0.15M | ||||||||||||||||||||||||||||||||||
| Operating ExpensesOpex | 27.81M | 31.97M | 36.96M | 43.48M | 43.91M | 48.27M | 50.66M | 53.98M | 59.32M | 62.66M | 74.17M | 83.18M | 87.80M | 94.75M | 111.77M | 130.14M | 142.73M | 139.83M | 151.11M | 157.58M | |||||||||||||||||
| Operating IncomeOp. Inc | -27.81M | -30.89M | -33.83M | -43.05M | -43.45M | -47.56M | -47.98M | -52.99M | -58.98M | -62.66M | -73.53M | -82.78M | -87.80M | -94.75M | -111.41M | -129.11M | -142.59M | -133.67M | -140.38M | -132.46M | |||||||||||||||||
| EBIT | -27.81M | -30.89M | -33.83M | -43.05M | -43.45M | -47.56M | -47.98M | -52.99M | -58.98M | -62.66M | -73.53M | -82.78M | -87.80M | -94.75M | -111.41M | -129.11M | -142.59M | -133.67M | -140.38M | -132.46M | |||||||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | |||||||||||||||||||||||||||||||||||||
| Non Operating Investment Income | -1.01M | -1.00M | -4.20M | -0.47M | |||||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.02M | 0.08M | 0.19M | 0.72M | 1.50M | 1.90M | 2.04M | 2.11M | 2.57M | 6.72M | 7.32M | 8.74M | 11.01M | 14.37M | 14.83M | 13.46M | 12.54M | 11.16M | 12.66M | 12.03M | |||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.04M | -0.22M | -0.20M | 0.02M | -0.05M | -0.12M | -0.13M | -0.42M | |||||||||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | -0.07M | 0.01M | 0.21M | 0.67M | 1.53M | 2.56M | 1.98M | 2.02M | 2.52M | 6.76M | 7.07M | 8.73M | 10.97M | 14.15M | 14.63M | 13.47M | 12.49M | 11.03M | 12.53M | 11.60M | |||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||||||||||
| EBT | 27.85M | -184.49M | 33.62M | 42.38M | 41.92M | 44.99M | 45.99M | 50.98M | 56.46M | -362.77M | 66.46M | 74.06M | -76.83M | -80.59M | 96.77M | 115.64M | -130.09M | -122.64M | -127.71M | -120.43M | |||||||||||||||||
| Profit After TaxPAT | 27.85M | -184.49M | 33.62M | 42.38M | 41.92M | 44.99M | 45.99M | 50.98M | 56.46M | -362.77M | 66.46M | 74.06M | -76.83M | -80.59M | 96.77M | 115.64M | -130.09M | -122.64M | -127.71M | -120.43M | |||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | 27.85M | -184.49M | 33.62M | 42.38M | 41.92M | 44.99M | 45.99M | 50.98M | 56.46M | -362.77M | 66.46M | 74.06M | -76.83M | -80.59M | 96.77M | 115.64M | -130.09M | -122.64M | -127.71M | -120.43M | |||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | 27.85M | -184.49M | 33.62M | 42.38M | 41.92M | 44.99M | 45.99M | 50.98M | 56.46M | -362.77M | 66.46M | 74.06M | -76.83M | -80.59M | 96.77M | 115.64M | -130.09M | -122.64M | -127.71M | -120.43M | |||||||||||||||||
| Income towards Parent CompanyParent Net Inc | -27.85M | -30.79M | -34.63M | -42.38M | -41.92M | -44.99M | -45.99M | -50.98M | -57.46M | -60.10M | -66.93M | -74.06M | -76.83M | -80.59M | -96.77M | -115.64M | -130.09M | -122.81M | -127.84M | -120.86M | |||||||||||||||||
| Net Income towards Common StockholdersNet Income | -27.85M | -30.79M | -34.63M | -42.38M | -41.92M | -44.99M | -45.99M | -50.98M | -57.46M | -60.10M | -66.93M | -74.06M | -76.83M | -80.59M | -96.77M | -115.64M | -130.09M | -122.81M | -127.84M | -120.86M | |||||||||||||||||
| Additional items | |||||||||||||||||||||||||||||||||||||
| EPS (Basic) | -0.73 | -0.80 | -0.73 | -0.81 | -0.78 | -0.87 | -0.85 | -0.94 | -1.01 | -1.03 | -0.93 | -0.94 | -0.96 | -1.00 | -1.04 | -1.23 | -1.38 | -1.31 | -1.23 | -1.14 | |||||||||||||||||
| EPS (Diluted) | -0.73 | -0.80 | -0.73 | -0.81 | -0.78 | -0.87 | -0.85 | -0.94 | -1.01 | -1.03 | -0.93 | -0.94 | -0.96 | -1.00 | -1.04 | -1.23 | -1.38 | -1.31 | -1.23 | -1.14 | |||||||||||||||||
| Shares Outstanding | 38.31M | 38.44M | 47.71M | 52.52M | 53.77M | 51.98M | 53.91M | 54.27M | 56.81M | 58.07M | 72.29M | 79.01M | 80.09M | 80.78M | 93.10M | 93.79M | 94.22M | 94.06M | 104.10M | 105.56M | |||||||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 38.31M | 38.44M | 47.71M | 52.52M | 53.77M | 51.98M | 53.91M | 54.27M | 56.81M | 58.07M | 72.29M | 79.01M | 80.09M | 80.78M | 93.10M | 93.79M | 94.22M | 94.06M | 104.10M | 105.56M | |||||||||||||||||
| EBITDA | -27.57M | -30.65M | -33.59M | -42.83M | -43.21M | -47.28M | -47.70M | -52.72M | -58.70M | -62.40M | -73.06M | -82.03M | -87.03M | -93.96M | -110.48M | -128.15M | -141.57M | -132.67M | -139.22M | -131.39M | |||||||||||||||||
| Interest ExpensesInt Expense |
Pull Crinetics Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=CRNX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "CRNX", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=CRNX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();